摘要
目的观察心脉隆注射液治疗慢性心力衰竭的临床疗效。方法将102例慢性心力衰竭患者随机分为对照组51例和治疗组51例,实际入组治疗组46例,对照组48例。对照组给予常规抗心力衰竭治疗。治疗组在常规抗心力衰竭治疗基础上给予心脉隆注射液5 mg/kg静脉输注,2次/d,5 d为一个疗程,连续用药10 d。观察治疗前后患者心功能改善情况、N端B型脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)、6 min步行距离的变化。结果治疗组显效23例,有效17例,无效6例;对照组显效15例,有效16例,无效17例。两组比较差异有统计学意义(P<0.05)。治疗组心功能、NT-proBNP、LVEF水平、6 min步行距离比对照组明显改善,差异具有统计学意义(P<0.05)。结论心脉隆注射液能够改善慢性心力衰竭患者的心脏功能,提高患者的运动耐量,改善LVEF水平,同时具有较高的安全性。
Objective To evaluate the efficacy of Xinmailong injection in the treatment of chronic heart failure（CHF）. Methods One hundred and two patients with were CHF randomly divided into the treatment group（n = 46） and the control group（n = 48）. Both of the two groups received the same routine therapy for CHF, and the treatment group had an additional injection of Xinmailong（ ivgtt, 5 mg/kg, bid for 10 days）. The improvement of heart function,the level of NT-proBNP, left ventricular ejection fraction（LVEF） and 6-min walking distance were observed before and after the treatment. Results Twenty-three cases were markedly effective, 17 cases effective and 6 cases ineffective in the treatment group. In the control group, 15 cases were markedly effective, 16 cases effective and 17 cases ineffective. There was significant difference in the clinical efficacy between the two groups（ P 〈 0. 05 ）. The total effective rate of heart function, the level of NT-proBNP, LVEF and 6-min walking distance in the treatment group were improved better than those in the control group （ P 〈 0. 05 ）. Conclusion Xinmailong injection can improve LVEF and the heart function of CHF patients and elevate the exercise tolerance.
出处
《中国临床新医学》
2017年第4期353-356,共4页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
